Skip Navigation
Regional News
Photo: <a href="http://www.flickr.com/photos/16456630@N00/410979198/">Wendy House</a>, Creative Commons, some rights reserved
Photo: Wendy House, Creative Commons, some rights reserved

NY settles probe of generic drug manufacturers

ALBANY, N.Y. (AP) New York's attorney general has announced a settlement with generic drug manufacturers Ranbaxy Pharmaceuticals and Teva Pharmaceuticals USA intended to ensure they don't collude to restrict competition.

According to Attorney General Eric Schneiderman, the settlement ends their 2010 agreement against competing over dozens of drugs.

Share this


Explore this

Tags

So-called "first to file" exclusivity protects a generic manufacturer from competition for 180 days, when prices are generally higher than after exclusivity expires.

In this case, investigators say Ranbaxy and Teva agreed not challenge each other's exclusivities for many drugs.

In the agreement signed this week, the companies admit no wrongdoing, each agree to pay the state $150,000 and to neither enforce nor follow the so-called "no challenge provision" or enter similar agreements for drugs sold in New York.

(Copyright 2014 The Associated Press. All rights reserved)

Visitor comments

on:

NCPR is supported by:

This is a Visitor-Supported website.